DelveInsight’s latest analysis highlights the transformative potential of Regeneron Pharmaceuticals’ positive Phase 3 NIMBLE trial results for cemdisiran in generalized myasthenia gravis (gMG). This landmark achievement marks a significant advancement in complement inhibition therapy, offering new hope for patients suffering from this chronic autoimmune neuromuscular disorder...